Health Condition 1: H308- Other chorioretinal inflammations
Conditions
Interventions
Control Intervention1: NIL: NIL
Sponsors
AIIMS, New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosed with NIU requiring systemic treatment Sight threatening uveitis cases which are started on Adalimumab therapy such as cases of chronic intermediate uveitis, choroiditis, vasculitis, or VKH will be predominantly included. Both chronic and recurrent cases of above subtypes of uveitis on Adalimumab will be included. Definitions of chronic and recurrent is as per standardized uveitis nomenclature (International). Unable to maintain remission on 5mg or less prednisolone with or without other immunomodulators Willingness to receive adalimumab therapy and participate in the study
Exclusion criteria
Exclusion criteria: Possible to maintain remission on prednisolone 5 mg or less Possible to maintain remission on immunomodulators with or without prednisolone in a dose of 5mg or less Active or uncontrolled systemic infection Active tuberculosis Uncontrolled or significant medical conditions (e.g., severe cardiovascular disease, uncontrolled diabetes, active malignancy) Pregnancy or breastfeeding History of hypersensitivity to adalimumab or its components Multiple sclerosis or other demyelinating diseases Inability or unwillingness to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Improved treatment recommendations for patients with inadequate response to conventional therapies. 2.Development of personalized treatment strategies based on individual characteristics and response to adalimumab. 3.Enhanced understanding of the long-term safety profile of adalimumab.Timepoint: Baseline: Ophthalmic evaluation (e.g., visual acuity, IOP, anterior chamber cells, vitreous haze, OCT), lab tests, and disease history assessment. Follow-Up: 1 Month: Initial response and side effects. 3 Months: Short-term efficacy and therapy adjustments. 6 Months: Monitor response and adverse events. 12 Months: Evaluate effectiveness and tolerability. Years 2-3: Assess long-term outcomes and adherence. Additional Visits: For flare-ups or complications. | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Rohan Chawla
Dr RP Centre for Ophthalmic Sciences All India Institute of Medical Sciences (AIIMS) Ansari Nagar, New Delhi 110029
Outcome results
None listed